Formulation development and characterization of propranolol hydrochloride microballoons for gastroretentive floating drug delivery

Abstract

The purpose of this research was to prepare floating microballoons consisting of (i) calcium silicate as porous carrier; (ii) propranolol hydrochloride (PRH), an oral anti-hypertensive agent; and (iii) Eudragit S as polymer, by solvent evaporation method and to evaluate their gastro-retentive and controlled release properties. The effect of various formulation and process variables on the particle morphology, micromeritic properties, in-vitro floating behavior, percentage drug entrapment, and in-vitro drug release was studied. The gamma scintigraphy of the optimized formulation was performed in albino rabbits to monitor the transit of floating microballoons in the gastrointestinal tract. The propranolol hydrochloride-loaded optimized formulation was orally administered to albino rabbits, and blood samples collected were used to determine pharmacokinetic parameters of propranolol hydrochloride from floating microballoons. The microballoons were found to be regular in shape and highly porous. Microballoons formulation CS4, containing 200 mg calcium silicate showed the best floating ability (89 ± 4% buoyancy) in simulated gastric fluid as compared with other formulations. Release pattern of propranolol hydrochloride in simulated gastric fluid from all floating microballoons followed Higuchi matrix model and Peppas-Korsmeyer model. Prolonged gastric residence time of over 6 h was achieved in all rabbits for calcium silicate based floating microballoons of propranolol hydrochloride. The enhanced elimination half life observed after pharmacokinetic investigations in the present study is due to the floating nature of the designed formulations.

Development and Evaluation of Gastroretentive Floating Tablets of an Antihypertensive Drug Using Hydrogenated Cottonseed Oil

“…The oral bioavailability of many drugs is limited by their unfavourable physicochemical characteristics or absorption in well-defined part of the gastrointestinal tract (GIT) referred as “absorption window” [ 1 ]. Prolonged gastric retention improves bioavailability, reduces drug waste, and improves the solubility for drugs that are less soluble in a high pH environment [ 2 ]. Various approaches have been investigated to increase the retention of oral dosage form in the stomach, including floating systems, swelling and expanding systems, bioadhesive systems, modified shape systems, high density systems, and other delayed gastric emptying devices [ 1 ].…”

Preparation and in-Vitro Estimation for Gastroretentive Floating Hollow – Microspheres of Famotidine

“…The MB was gold coated using an ion sputtering device in a atmosphere of argon. After that, SEM was used to study the surface morphology of MB on microscopic scale under appropriate magnification [16].…”

Intranasal chitosan-g-HPβCD nanoparticles of efavirenz for the CNS targeting

“…EFV-S (prepared in 0.9% saline containing 30% propylene glycol as a cosolvent) was mixed with stannous chloride as a reducing agent for 10-15 min and then was radiolabelled with 99m T c (1mci) by direct labelling method in the similar way EFV-NPs (equivalent to 25 mg/mL EFV) were radiolabelled [26]. The mixture was incubated for 30 min.…”